We advised the placement agents on the transaction

Davis Polk advised the placement agents in connection with a PIPE transaction and the anticipated public launch of Talawar Tx Inc. through its business combination with JATT II Acquisition Corp. In connection with the business combination, the parties have also entered into subscription agreements for $225 million of committed common equity PIPE financing. The PIPE is led by founding investor Access Biotechnology and includes participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management and other leading healthcare-dedicated investors and mutual funds. At closing, the combined company will operate as Talawar Therapeutics and is expected to be listed on Nasdaq under the ticker symbol “TLWR.”

Talawar Therapeutics is a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent disease drivers in a single therapy, targeting pathways that work together for greater, more durable impact. Its lead program, TALA-125, is a novel anti-IL-13 x anti-IL-18 bispecific that combines two clinically validated, largely orthogonal mechanisms designed to shatter the current limitations of existing treatments, with broad applicability across first-line patients and those who have failed previous therapies.JATT II was formed for the purpose of entering into a business combination with one or more businesses. Its shares are listed on Nasdaq under the ticker symbol “JATT.”

The Davis Polk capital markets team included partner Derek Dostal and associates Robert Van de Mark and Paul M. Sessa. All members of the Davis Polk team are based in the New York office.

Copy link to share post